Advances for Lung and Prostate Cancer Patients

Food and Drug Administration (FDA) approval of two new advances promise to transform the detection of prostate cancer and the treatment of lung cancer.

On May 26, the FDA approved Pylarify, a molecule injected prior to positron emission tomography (PET) imaging that reveals prostate cancer cells on the scan. Pylarify does not replace prostate-specific antigen (PSA) screening, but will allow physicians to determine the extent of prostate cancer in patients suspected of having or diagnosed with the disease. Dr. Michael Morris led the phase III clinical trial at MSK. Read more from NBC News,, and MSK.

On May 28, the FDA approved the use of sotorasib (Lumakras) in patients with advanced non-small cell lung cancer who have the KRAS-G12C genetic mutation and have already tried another treatment modality. This treatment was the culmination of almost 40 years of research, and was spearheaded through clinical trials by MSK’s Dr. Bob Li. Learn more from Good Morning America,, and MSK.